TC BioPharm PLC, a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is developing a streamlined and scaled-up manufacturing process that aims to increase its treatments capacity from 52 patient treatments per year to more than 1,000.
 
The objective of this undertaking, which will utilize the company’s current infrastructure, is to provide a cost reduction of 85% per patient treatment. The company expects to implement the improved manufacturing process into its current facility in the next 24 months.
 
“These new initiatives will allow us to increase capacity while simultaneously reducing the cost of our per patient treatment once optimized,” said Dr. Lauren Bor, Ph.D., Process Development and Commercialization, Senior Manager.
 
Bor continued: “This enterprise is necessary to address the challenging operating landscape in cell therapy and better position TC BioPharm both economically and operationally to improve the lives of patients while creating long-term value for shareholders. 
 
“One of the biggest bottlenecks in cell therapy today is the high cost of manufacturing, which leads to extremely high treatment costs to patients, and this endeavor should allow TCB to reverse these issues. We are addressing these issues today to provide a low-cost, high-margin therapeutic to patients in the future, which maintains our leadership position from a first-move and best-in-class perspective. Additionally, I believe that these developments will lay the groundwork for a commercialization plan and increasing TC BioPharm’s manufacturing footprint.”
 
This news comes a year after the company announced a corporate restructuring plan to reduce costs and prioritize its pending lead U.S. clinical programs.